IZERVAY Online Meeting

最初から再生

Investor call:
IZERVAY (AVACINCAPTAD PEGOL intravitreal solution)
GATHER2 2-YEAR data Presented at AAO 2023

• Cautionary Statement Regarding Forward-Looking Information

DHAVAL DESAI

Today’s presentation contents

AAO Update AND GATHER2 Summary and background

• AAO Update

• Summary of gather2: 2-year data

• IZERVAY is designed to be a specific inhibitor of complement C5

• IZERVAY ACHIEVED THE 12-MONTH PRESPECIFIED PRIMARY OBJECTIVE IN 2 PIVOTAL PHASE 3 STUDIES

• GATHER2 is a 2-year, phase 3, international, multicenter, prospective, randomized, double-masked, sham-controlled study (NCT04435366)

GATHER2 2-YEAR DATA

• IZERVAY reduced GA growth when dosed EM AND EOM vs sham

• Treatment effect more than doubled with IZERVAY over 2 years compared to 1 year

• No statistically significant difference in 15-letter persistent vision loss between IZERVAY and sham

• Treatment emergent adverse events (TEAEs) over 2 years were similar and consistent with year 1

• Serious ocular TEAEs - No new safety signals in year 2

• Choroidal neovascularization (CNV)

• Adverse events of special interest

• Summary of gather2: 2-year data

• LIFECYCLE MANAGEMENT UPDATE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6